Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes

Garg, Minakshi; Garg, Babu Ram; Jain, Sanyog; Mishra, Pushpa; Sharma, Rakesh Kumar; Mishra, Anil K.; Dutta, Tathagata; Jain, Narendra Kumar

doi:10.1016/j.ejps.2007.12.006

Cited by 41 publications

(33 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the half life of conventionally delivered indinavir in rodents was 2 h, while a single dose of intravenously injected nanoindavir suspension in rodents was measurable in the blood up to 14 days post-treatment (41). It was observed that the cellular uptake of satuvudine (HIV nucleoside analog reverse transcriptase inhibitor) encapsulated in various liposomes and conjugated with mannose and galactose was also increased as compared to plain liposomes or free drugs (41,42).…”

Section: Nanotechnology Against Hiv Infectionmentioning

confidence: 78%

Modern biotechnology-based therapeutic approaches against HIV infection (Review)

et al. 2017

View full text Add to dashboard Cite

Abstract. The causative agent of acquired immune deficiency syndrome (AIDS) is human immunodeficiency virus (HIV).Since its discovery before 30 years, a number of drugs known as highly active antiretroviral therapy have been developed to suppress the life cycle of the virus at different stages. With the current therapeutic approaches, ending AIDS means providing treatment to 35 million individuals living with HIV for the rest of their lives or until a cure is developed. Additionally, therapy is associated with various other challenges such as potential of drug resistance, toxicity and presence of latent viral reservoir. Therefore, it is imperative to search for treatments and to identify new therapeutic approaches against HIV infection to avoid daily intake of drugs. The aim of the current review was to summarize different therapeutic strategies against HIV infection, including stem cell therapy, RNA interference, CRISPR/Cas9 pathways, antibodies, intrabodies and nanotechnology. Silencing RNA against chemokine receptor 5 and other HIV RNAs have been tested and found to elicit homology-based, post-transcriptional silencing. The CRISPR/Cas9 is a gene editing technology that produces a double-stranded nick in the virus DNA, which is repaired by the host machinery either by non-homology end joining mechanism or via homology recombination leading to insertion, deletion mutation which further leads to frame shift mutation and non-functional products. Intrabodies are intracellular-expressed antibodies that are directed towards the targets inside the cell unlike the naturally expressed antibodies which target outside the cell. Different nanotechnology-based therapeutic approaches are also in progress against HIV. HIV eradication is not feasible without deploying a cure or vaccine alongside the treatment.

show abstract

Section: Nanotechnology Against Hiv Infectionmentioning

confidence: 78%

Modern biotechnology-based therapeutic approaches against HIV infection (Review)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In both case an enhanced half-life and residence time of the encapsulated drug was registered with no hematological or hepatic toxicity. The galactosylated liposomes were further radio labeled with 99mTc, the biodistribution was evaluated and the antiretroviral activity was determined using HIV-1-infected MT2 cell line [105]. The scintigraphic imaging and quantitative biodistribution of 99mTc labeled drug and liposomes reported in this study, showed that liposomal formulations were better taken up by the liver andspleen and an uptake prolonged up to 24 h thus suggesting a reduced toxicity and target ability ofthe stavudine-loaded liposomes to the MPS.…”

Section: Dendrimersmentioning

confidence: 98%

Nanotechnology Approaches for Antiretroviral Drugs Delivery

Iannazzo¹,

Pistone²,

Romeo³

et al. 2015

Journal of AIDS and HIV infections

View full text Add to dashboard Cite

The development of effective drug delivery approaches for the treatment of AIDS and HIV infection is a global challenge. The advent of multidrug, highly active antiretroviral therapy (HAART), have increased the life span of HIV-infected patients. However, it has not eradicated HIV infections, particularly in anatomically privileged sites, such as the brain, testes, gut, liver, kidney, and secondary lymphoid tissue. Several nanocarriers have been investigated in order to enhance the effective delivery of antiretroviral drugs for HIV prevention and therapy. This review focuses on the most recent and significant examples of nanotechnology-based approaches for the delivery of antiretroviral agents belonging to the classes of nucleoside-analog reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). Nanocarriers such as natural and synthetic polymeric nanoparticles, dendrimers, liposomes, and various drug conjugates have been discussed. These nanotechnology carriers are able to deliver the antiretroviral agents in a controlled and/or targeted manner thereby increasing the drug bioavailability and residence time at target sites with a considerable improvement in quality of HIV patients.

show abstract

“…Regarding low-molecular-weight drug delivery, studies have reported the delivery of anti-cancer drugs to hepatocellular carcinomas (HCC N4-Octadecyl-1-β-D-arabinofuranosylcytosine [148], and stabudine [136,149] have been used for hepatocyte-selective targeting. Because asialoglycoprotein receptors are expressed on normal hepatocytes, tumor selectivity is required for a rational cancer therapy.…”

Section: Cholesten-5-yloxy-n-(4-((1-imino-2-d-thiogalactosylethyl)amimentioning

confidence: 99%

Glycosylation-mediated targeting of carriers

Kawakami

Hashida

2014

Journal of Controlled Release

View full text Add to dashboard Cite

For safe and effective therapy, drugs should be delivered selectively to their target tissues or cells at an optimal rate. Drug delivery system technology maximizes the therapeutic efficacy and minimizes unfavorable drug actions by controlling their distribution profiles. Ligand-receptor binding is a typical example of specific recognition mechanisms in the body; therefore, ligand-modified drug carriers have been developed for active targeting based on receptor-mediated endocytosis. Among the various ligands reported thus far, sugar recognition is a promising approach for active targeting because of their high affinity and expression. Glycosylation has been applied for both macromolecular and liposomal carriers for cell-selective drug targeting.Recently, the combination of ultrasound exposure and glycosylated bubble liposomes has been developed. In this review, recent advances of glycosylation-mediated targeted drug delivery systems are discussed.

show abstract

Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes

Cited by 41 publications

References 24 publications

Modern biotechnology-based therapeutic approaches against HIV infection (Review)

Modern biotechnology-based therapeutic approaches against HIV infection (Review)

Nanotechnology Approaches for Antiretroviral Drugs Delivery

Glycosylation-mediated targeting of carriers

Contact Info

Product

Resources

About